Clinical trials: Hepatic Failure
Hepatic Encephalopathy
Rifaximin in Minimal Hepatic Encephalopathy
The purpose of this study is to determine whether alteration of gut flora with rifaximin can lead to improvement in driving performance, psychometric test performance, and quality of life in patients with minimal hepatic…
- Trial name
- NCT00533910
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Hepatitis C, Chronic
A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)
This is a non-randomized, open-label, single-dose study to evaluate the pharmacokinetics (PK) of uprifosbuvir (MK-3682), the M5 and M6 metabolites of uprifosbuvir, and ruzasvir (MK-8408), in participants with moderate hepatic…
- Trial name
- NCT02666352
- Testing
- Uprifosbuvir, Ruzasvir
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Critical Illness, Chronic Disease
Improving Communication About Serious Illness
The purpose of this study is to improve care delivered to patients with serious illness by enhancing communication among patients, families, and clinicians in the outpatient setting.
- Conditions
- Critical Illness, Chronic Disease, Terminal Care, Palliative Care
- Trial name
- ICSI (NCT01933789)
- Testing
- Communication Feedback Form for Patients with Serious Illness
- Where
- 6 sites in United States
- Volunteers
- 817 people
- Sponsor
- University of Washington
Liver Failure
Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant
The purpose of this study is evaluate the medication vasopressin for its ability to preserve kidney function in patients undergoing liver transplantation.
- Trial name
- NCT00886262
- Testing
- Vasopressin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Liver Failure
A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation
This is a 24-month, Phase II, multi-center, two-arm, randomized controlled study of adult patients receiving a single organ liver transplant from a deceased donor; the purpose being to determine the efficacy of Thymoglobulin®…
- Trial name
- NCT02544113
- Testing
- Thymoglobulin
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- The Cleveland Clinic
Hepatitis C, Medication Adherence
Intensive Models of HCV Care for Injection Drug Users
Injection drug users (IDUs) constitute 60% of the approximately 5 million people in the U.S. infected with hepatitis C virus (HCV). HCV treatment leading to sustained viral response (SVR) is associated with increased survival.
- Trial name
- NCT01857245
- Testing
- Intensive Models (mDOT and CGT) of HCV Care
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Prisma Health-Upstate
End Stage Liver Disease, Hepatitis C
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
The purpose of this study is to compare three treatment regimens in patients who have received a liver transplant for end-stage liver disease caused by Chronic Hepatitis C infection.
- Trial name
- NCT00163657
- Testing
- Daclizumub, Tacrolimus, Cyclosporine
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Baylor Research Institute
Amatoxin Poisoning, Amanita Poisoning
Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning
Legalon® SIL will be administered to patients with amatoxin poisoning diagnosed by history, gastrointestinal symptoms, elevated liver enzymes, and/or diagnostic assay (should one become available).
- Conditions
- Amatoxin Poisoning, Amanita Poisoning, Mushroom Poisoning, Liver Failure
- Trial name
- NCT00915681
- Testing
- Silibinin
- Where
- 2 sites in United States
- Volunteers
- 148 people
- Sponsor
- Mylan Specialty, LP
Acute Liver Failure, Fulminant Hepatic Failure
Study of N-Acetylcysteine in Acute Liver Failure (ALF)
This proposed study is a multi-center open label study to determine if N-acetylcysteine has any survival benefits in patients with acute liver failure.
- Trial name
- ONAC (NCT00896025)
- Testing
- N-acetylcysteine
- Where
- 21 sites in United States
- Volunteers
- 255 people
- Sponsor
- University of Texas Southwestern Medical Center
Acute Kidney Injury, Cirrhosis
NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients
The goal of this pilot, randomized, single-blind clinical trial is to estimate the effect size of a high and low mean arterial pressure (MAP)-target algorithm among cirrhosis patients hospitalized with acute kidney injury.
- Conditions
- Acute Kidney Injury, Cirrhosis, Portal Hypertension, Hepatorenal Syndrome
- Trial name
- NEPH-ROSIS (NCT06000748)
- Testing
- MAP-Target Algorithm
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Francisco
Hepatic Insufficiency
The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)
The purpose of this study is to evaluate the pharmacokinetics (PK) profile of elbasvir (MK-8742) after a single dose to participants with mild, moderate, or severe hepatic insufficiency compared with healthy controls.
- Trial name
- NCT01797536
- Testing
- Elbasvir
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatic Insufficiency
A Study of Tirzepatide in Participants With Impaired Liver Function
The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants.
- Trial name
- NCT03940742
- Testing
- Tirzepatide
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hepatic Insufficiency, Antibacterial Agents
Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)
This is an open-label, single-dose, Phase 1 study to evaluate the pharmacokinetics (PK) of intravenous (IV) MK-3866 in participants with moderate and severe hepatic impairment (HI) compared to that of matched healthy…
- Trial name
- NCT03295266
- Testing
- MK-3866
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Acute Alcoholic Hepatitis
Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD
The primary objective of the study is to evaluate safety and efficacy of ELAD with respect to overall survival of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) through at least Study Day 91.
- Trial name
- NCT02612428
- Testing
- ELAD System, Standard of Care (Control)
- Where
- 44 sites in United States, Austria and 4 more
- Volunteers
- 151 people
- Sponsor
- Vital Therapies, Inc.
Hepatic Encephalopathy, Cirrhosis
Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.
This study is being done to find out if the laxative polyethylene glycol (also known as GoLYTELY® or Miralax®) can treat your hepatic encephalopathy (confusion due to your liver disease and/or cirrhosis) better and/or more safely…
- Conditions
- Hepatic Encephalopathy, Cirrhosis, Portosystemic Encephalopathy, PSE
- Trial name
- PSE (NCT01283152)
- Testing
- Polyethylene glycol 3350-electrolyte solution (GoLYTELY®), Lactulose
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Texas Southwestern Medical Center
Liver Cirrhosis
Adult Stem Cell Therapy in Liver Insufficiency
In order to determine the clinical application potential of adult stem cells we propose to investigate the safety and toxicity of infusing adult stem cells in the hepatic artery or portal vein of five patients with chronic liver…
- Trial name
- NCT00147043
- Testing
- Leukapheresis, Infusion of stem cells via image guided scan
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Imperial College London
Acute Liver Failure, Fulminant Hepatic Failure
Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)
This phase 2 study is developed to evaluate the effect of ELAD on overall survival (OS) in subjects with acute liver failure (ALF) compared to matched historical controls.
- Conditions
- Acute Liver Failure, Fulminant Hepatic Failure, Primary Graft Non-Function, Surgically-Induced Liver Failure
- Trial name
- NCT01875874
- Testing
- ELAD
- Where
- 18 sites in United States
- Volunteers
- 8 people
- Sponsor
- Vital Therapies, Inc.
Hepatic Impairment
Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects
The purpose of the protocol is to assess the pharmacokinetics, safety and tolerability of a single dose of telotristat etiprate in subjects with various stages of hepatic impairment compared to healthy control subjects.
- Trial name
- NCT02683577
- Testing
- telotristat etiprate
- Where
- 2 sites in Moldova, Romania
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ipsen
Severe Hepatic Veno-Occlusive Disease
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
The purpose of this study is to (1) demonstrate the efficacy and safety (toxicity) of 25 mg/kg/day of Defibrotide in patients with severe veno-occlusive disease (sVOD) and (2) evaluate serum and endothelial markers of…
- Trial name
- NCT00358501
- Testing
- Defibrotide
- Where
- 25 sites in United States, Canada
- Volunteers
- 134 people
- Sponsor
- Jazz Pharmaceuticals
End Stage Liver DIsease, Liver Failure
Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation
This is a prospective, multi-center, controlled, randomized, pivotal study to evaluate the safety and effectiveness of the VitaSmart™ Liver Machine Perfusion System by comparing clinical outcomes in patients undergoing liver…
- Trial name
- NCT05045794
- Testing
- VitaSmart™Liver Machine Perfusion System, Static cold storage
- Where
- 15 sites in United States
- Volunteers
- 228 people
- Sponsor
- Bridge to Life Ltd.